Can you get a golden dose out of a Wegovy pen?

What the STEP 1 trial data tell us about getting the most from each dose

Wegovy's weight-loss evidence comes from the STEP programme. In STEP 1, published in the New England Journal of Medicine, adults with obesity taking semaglutide 2.4 mg weekly achieved an average weight reduction of around 15% over 68 weeks alongside lifestyle support. Every participant in that trial used pens exactly as instructed. The results hold because doses were consistent and complete, taken at the scheduled weekly interval, with no improvised extraction.

That context matters when you read about golden doses online. The clinical evidence does not include what happens when someone injects residual medicine at an uncertain volume, at an unplanned time, or from a pen that has already delivered its final labelled dose. It is not that a small residual amount is necessarily harmful; it is that the benefit is unmeasured, the volume is unknown, and the decision is not yours alone to make, so understanding whether you actually get a golden dose with Wegovy is a useful place to start before drawing any conclusions.

If you are curious about how Wegovy doses are structured across the full titration schedule, that page sets out the licensed steps from 0.25 mg through to the maintenance dose as authorised by the MHRA.

How Wegovy pens are designed, and why residual medicine turns up at all

Wegovy is supplied as a pre-filled, pre-set auto-injector. The mechanism delivers a fixed volume per activation; you do not draw up medicine or adjust a dial. Novo Nordisk designs each pen to contain slightly more than the labelled dose, a standard pharmaceutical practice called overfill, which ensures the stated dose is reliably delivered even accounting for priming and dead-space in the needle.

What some people notice, particularly at higher strengths, is that after the pen clicks to indicate the final dose has been administered, a small amount of liquid remains visible in the cartridge. That residual is what gets called a "golden dose." Its presence is not a manufacturing error; it is a predictable result of overfill. Whether it amounts to a therapeutically meaningful quantity of semaglutide varies, and Novo Nordisk's guidance does not endorse extracting it.

If you want a clearer picture of what to expect pen by pen, our Wegovy golden dose chart sets out what is typically observed at each strength, with the important caveat that this is observational, not licensed guidance.

Is it safe to inject a golden dose, and what do prescribers say?

This is the question our clinical team hears fairly often, and it is a fair one, especially when pens are expensive and supply has at times been tight. The honest position is that there is no formal clinical guidance permitting or forbidding the use of residual medicine from a Wegovy pen. The MHRA licenses Wegovy for specific doses delivered via the pre-set injector; the SmPC and Patient Information Leaflet on the electronic Medicines Compendium cover standard pen use, not improvised extraction.

Practically, the concerns are not dramatic, semaglutide is not dangerous to handle and the residual volume is small. But using a needle to draw out residual medicine introduces variables: contamination risk if sterile technique slips, an uncertain dose, and a change to your dosing interval that your prescriber has not reviewed. For people titrating carefully to manage side effects, an unplanned injection of an unknown volume is not a trivial thing.

The safest approach is to raise it with your prescriber directly. If cost is part of the reason you are exploring this, it is worth reading about what drives Wegovy pricing in the UK and what a legitimate private prescription should include. And if you are wondering whether five full doses are achievable from a single pen, that specific question is covered separately.

The right place to make decisions about your Wegovy pen

Golden dose questions sit at the intersection of cost, curiosity and clinical safety. There is no blanket rule that makes extracting residual medicine dangerous, but there is a clear rule about who should be involved in the decision: your prescriber. They know your dose, your side-effect history, and where you are in the titration schedule. An improvised extra injection that shifts your weekly timing can affect tolerability and, over months, your results.

At nume, every repeat order goes through a clinical review before dispatch. That review is done by a GPhC-registered Independent Prescriber, and it is the natural moment to ask about pen use, residual doses, or anything else that is making you stretch your supply. There are no silly questions in that consultation; clinicians would rather you asked than guessed.

You can also find broader context about Wegovy as a licensed UK weight-loss treatment, including how it fits alongside the newer options now available. If you are thinking about whether treatment is right for you at all, our weight-loss treatment overview covers the landscape without pushing you toward any single option.